<DOC>
	<DOCNO>NCT01500551</DOCNO>
	<brief_summary>Evaluate long-term safety tolerability tofacitinib patient JIA , previously participate tofacitinib JIA study .</brief_summary>
	<brief_title>Long-Term Safety Study Of Tofacinib In Patients With Juvenile Idiopathic Arthritis</brief_title>
	<detailed_description>This Phase 2/3 , long term , open‑label , follow‑up study . Subjects previously participate qualifying/index JIA study tofacitinib . Those already complete participation enroll outside 14 day window follow completion End Study ( EOS ) Visit qualifying/index study participate screen Visit determine eligibility . A Baseline Visit occur within 28 day Screening Visit . For subject complete participation qualify study tofacitinib enrol day EOS Visit qualifying/index study , EOS Visit qualifying/index study combine Screening Baseline Visits study . The subject enroll within 14 day window follow completion EOS Visit qualifying/index study participate combine Screening Baseline Visit study . After Baseline Visit , visit occur 1 month ( 1 month=30 day ) 3 month , every 3 month thereafter long subject remain study . Approximately 290 participant project enroll open label extension study complete qualifying/index study JIA program . This study ( A3921145 ) plan run first global marketing approval tofacitinib treatment JIA . The total duration individual subject 's participation may vary depend upon enter trial .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Pediatric subject JIA age 2 less 18 year meet entry criterion qualifying/index study opinion investigator sufficient evidence JIA disease activity warrant use tofacitinib DMARD . Subjects turn 18 year age participation qualifying/index study subsequently eligible participation study . The subject discontinue disallow concomitant medication require time prior first dose study drug , define Appendix 1 , take concomitant medication dose frequency allow protocol . Fertile male subject female subject childbearing potential , opinion investigator , sexually active risk pregnancy partner ( ) must use highly effective method contraception outline protocol throughout study least 28 day last dose study medication . Subjects must previously complete participation qualify study tofacitinib treatment JIA . Subjects require early discontinuation treatment qualify study reason tofacitinib relate serious adverse event may eligible . Systemic JIA ( sJIA ) active systemic feature active joint elevate acute phase reactant , persistent oligoarthritis , undifferentiated JIA . Infections : 1 . Chronic infection . 2 . Any infection require hospitalization , parenteral antimicrobial therapy judge opportunistic investigator within 6 month prior first dose study drug . 3 . Any treated infection within 2 week baseline visit . 4 . A subject know infected human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C virus . 5 . History infect joint prosthesis prosthesis still situ . History recurrent ( one episode ) herpes zoster disseminate ( single episode ) herpes zoster disseminate ( single episode ) herpes simplex .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Arthritis</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Tofacitinib</keyword>
	<keyword>Long-term</keyword>
	<keyword>JIA</keyword>
	<keyword>CP-690,550</keyword>
	<keyword>Xeljanz</keyword>
</DOC>